PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea · Delayed Price · Currency is KRW 297,000
+2,000 (0.68%)
Jun 17, 2026, 9:50 AM KST
PharmaResearch Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 176,522 | 165,121 | 92,043 | 76,551 | 40,577 | 46,689 |
Depreciation & Amortization | 16,235 | 15,815 | 13,645 | 11,996 | 10,602 | 9,552 |
Loss (Gain) From Sale of Assets | -3.63 | 162.14 | 11.92 | -36.11 | 5,846 | -229.6 |
Asset Writedown & Restructuring Costs | 1,394 | 1,394 | - | 3,120 | - | 839.66 |
Loss (Gain) From Sale of Investments | -4,061 | -1,729 | 20,191 | -3,042 | 2,259 | -943.49 |
Loss (Gain) on Equity Investments | -643.74 | -425.47 | -5,954 | -680.03 | 2,192 | -556.93 |
Stock-Based Compensation | - | 149.42 | 658.9 | 657.1 | 505.88 | - |
Provision & Write-off of Bad Debts | 65.73 | 452.14 | -244.35 | 582.21 | 290.45 | -406.73 |
Other Operating Activities | 31,319 | 26,879 | 17,385 | 6,512 | 7,598 | 1,932 |
Change in Accounts Receivable | -11,868 | -4,445 | -8,535 | 717.13 | -4,843 | -3,842 |
Change in Inventory | -32,217 | -26,249 | -11,940 | -28,188 | -8,374 | 2,927 |
Change in Accounts Payable | 8,019 | 169.16 | 7,724 | -559.07 | 597.78 | 397.75 |
Change in Unearned Revenue | -39.03 | -7.94 | 72.1 | 16.32 | 11.36 | - |
Change in Income Taxes | - | - | - | - | 9.63 | 1.52 |
Change in Other Net Operating Assets | -5,817 | 5,876 | 13,063 | -3,230 | 2,131 | 9,088 |
Operating Cash Flow | 178,904 | 183,162 | 138,122 | 64,945 | 59,404 | 65,297 |
Operating Cash Flow Growth | 28.79% | 32.61% | 112.67% | 9.33% | -9.03% | 101.59% |
Capital Expenditures | -28,997 | -29,727 | -36,415 | -12,063 | -17,257 | -20,645 |
Sale of Property, Plant & Equipment | 225.23 | 179.7 | 30.68 | 28.65 | 734.02 | - |
Cash Acquisitions | - | - | - | - | -35.01 | - |
Sale (Purchase) of Intangibles | -1,741 | -4,877 | -2,310 | -623.05 | -460.83 | -2,786 |
Investment in Securities | -79,059 | -125,081 | -179,213 | -31,860 | 5,446 | -66,427 |
Other Investing Activities | -15.66 | -82.43 | 2,507 | -522.63 | -794.6 | -590.91 |
Investing Cash Flow | -104,845 | -155,918 | -225,538 | -44,668 | -11,908 | -93,755 |
Long-Term Debt Issued | - | - | 10,782 | - | - | 50,000 |
Total Debt Issued | - | - | 10,782 | - | - | 50,000 |
Short-Term Debt Repaid | - | - | - | - | -860 | -29.13 |
Long-Term Debt Repaid | - | -3,370 | -17,946 | -18,799 | -2,126 | -1,976 |
Total Debt Repaid | -6,353 | -3,370 | -17,946 | -18,799 | -2,986 | -2,005 |
Net Debt Issued (Repaid) | -6,353 | -3,370 | -7,164 | -18,799 | -2,986 | 47,995 |
Issuance of Common Stock | - | - | - | 359.24 | - | - |
Dividends Paid | -11,729 | -11,729 | -10,090 | -7,529 | -6,316 | -5,030 |
Other Financing Activities | -80.37 | -174 | -102.45 | -0 | - | -0 |
Financing Cash Flow | -18,162 | -15,273 | 182,643 | -25,969 | -9,301 | 42,965 |
Foreign Exchange Rate Adjustments | 1,653 | -1,657 | 1,118 | 4.41 | -76.12 | 300.33 |
Miscellaneous Cash Flow Adjustments | -0 | -0 | 1,758 | 0 | -6,862 | 151.51 |
Net Cash Flow | 57,549 | 10,315 | 98,103 | -5,687 | 31,257 | 14,959 |
Free Cash Flow | 149,907 | 153,435 | 101,707 | 52,883 | 42,147 | 44,652 |
Free Cash Flow Growth | 53.27% | 50.86% | 92.33% | 25.47% | -5.61% | - |
Free Cash Flow Margin | 26.51% | 28.61% | 29.05% | 20.26% | 21.64% | 28.98% |
Free Cash Flow Per Share | 12905.46 | 13266.86 | 9879.60 | 5008.31 | 4224.85 | 4441.83 |
Cash Interest Paid | 89.2 | 2,182 | 428.67 | 493.61 | 159.45 | 196.15 |
Cash Income Tax Paid | 46,606 | 39,616 | 19,811 | 16,962 | 13,798 | 10,051 |
Levered Free Cash Flow | 135,768 | 109,270 | 67,225 | 21,153 | 25,115 | 27,225 |
Unlevered Free Cash Flow | 142,198 | 115,765 | 70,121 | 23,020 | 27,509 | 28,046 |
Change in Working Capital | -41,922 | -24,657 | 384.04 | -30,714 | -10,467 | 8,421 |